HSA
RNAC icon

Hussman Strategic Advisors’s Cartesian Therapeutics RNAC Stock Holding History

Hussman Strategic Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,500
Closed -$186K – 308
2020
Q3 		$186K Hold
2,500
– – 0.05% 250
2020
Q2 		$213K Hold
2,500
– – 0.05% 245
2020
Q1 		$181K Buy
+2,500
New +$241K 0.05% 259

Other funds holding RNAC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Hussman Strategic Advisors's RNAC Position: Q4 2020 in Review

Hussman Strategic Advisors sold out of Cartesian Therapeutics (RNAC) in Q4 2020, closing a stake of 2,500 shares — an estimated $186K sold.

Hussman Strategic Advisors first reported a position in RNAC in Q1 2020 and held it in 3 quarters. The position peaked at $213K in Q2 2020. 95 funds tracked by Wall St. Rank hold RNAC as of Q4 2020.

  • Hussman Strategic Advisors reported no remaining Cartesian Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Hussman Strategic Advisors sold 2,500 Cartesian Therapeutics shares in Q4 2020, an estimated $186K.
  • Hussman Strategic Advisors first reported a position in Cartesian Therapeutics in Q1 2020 and held it in 3 quarters.
  • Hussman Strategic Advisors's Cartesian Therapeutics position peaked at $213K in Q2 2020.
  • 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2020.

Based on Hussman Strategic Advisors's 13F filing for Q4 2020, filed 1 Feb 2021.